The Impact of the COVID-19 Omicron Variant on Immunocompromised Patients: ICU Admissions and Increased Mortality
Immunocompromised patients admitted to the ICU due to COVID-19 during the omicron period had higher mortality than non-immunocompromised patients. Additionally, immunocompromised patients with COVID-19 had higher mortality than immunocompromised patients with other viral pneumonias. Our results provide additional evidence that COVID-19 is still a significant health concern to immunocompromised individuals, which warrants specific and effective measures to protect this vulnerable group.
Authors
- Ferishta Bakhshi‐Raiez (ORCID: https://orcid.org/0000-0002-5992-3032)
- Dylan W. de Lange (ORCID: https://orcid.org/0000-0002-0191-7270)
- Fabian Termorshuizen (ORCID: https://orcid.org/0000-0003-4831-9507)
- Dave Anton Dongelmans (ORCID: https://orcid.org/0000-0001-8477-6671)
- Jan Pander
- Wendy Beekman-Hendriks
- Josien Lanfermeijer
Institutions
- Netherlands Aerospace Centre (NL)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Medical Center Utrecht (NL)
- Amsterdam Neuroscience (NL)
- AstraZeneca (Netherlands) (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1007/s40121-025-01122-5
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- AstraZeneca